GSK Says Shingrix Shortage, Oncology Push Continues
GlaxoSmithKline Q3 Update Notes PARP Promise, Shingrix Demand
Executive Summary
GlaxoSmithKline said its increasingly streamlined operations are on a growth trajectory, but that capacity constraints mean demand for its popular shingles vaccine will keep outstripping supply.
You may also be interested in...
Pharma Leaders Confront Another Daunting Challenge: Meeting COVID-19 Demand
Pharma leaders at the CNBC Healthy Returns virtual conference said they are optimistic industry will deliver a SARS-COV-2 vaccine, but ramping up the supply will require time and collaboration.
Moderna's Vaccine Portfolio Primed For Boost From Its COVID-19 Work
At its "Vaccines Day" with investors, Moderna execs tout the company's messenger RNA platform and say its portfolio of vaccine candidates has the potential to reach annual peak sales of up to $12bn.
New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza
Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1 – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.